Vectron Biosolutions just announced a strategic, international partnership with Cytovance Biologics, a renowned leader in contract development and manufacturing services for biopharmaceuticals.  This partnership will give the industry new, more efficient options for E. coli-expressed products across many indications of drug development.  Cytovance’s expansion of E. coli technologies and strains enables them to meet customers' needs for a one-of-a-kind approach to executing technical microbial projects.  The international deal allows Vectron to bring its technology to the North American Market and expand its global partnership network.  Visit Vectron Biosolutions to read the full press release and to learn more about their platform technology: